Redwood Pharma to Present at BIO 2016 in San Francisco

Tue, Jun 07, 2016 15:00 CET

Redwood Pharma AB (publ) has been invited to the BIO 2016 conference to present Redwood Pharma's drug candidate RP101 and drug delivery platform IntelliGel®. BIO 2016 is the world's largest conference on biotech. The conference takes place in San Francisco, CA, USA between June 6 to 9.

Over 15,000 participants will meet in San Francisco to among other things learn about trends and exchange ideas in different areas of biotech, life sciences and about new companies with innovative development projects. BIO is the world's largest trade association in biotech representing biotech companies, academic institutions, etc. from the United States and over 30 other countries (
www.bio.org
).

"BIO organizes the largest biotech conference in the world. This year the organizers invited Redwood Pharma to present the company. This is a fantastic opportunity for us to highlight Redwood Pharma and our unique technology for treating chronic dry eye and drug delivery platform IntelliGel
®
",
says CEO Martin Vidaeus.

About Redwood Pharma AB (publ)
Redwood Pharma develops ophthalmic products for unmet medical needs. The company's first project is the development of a drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel
®
, the release of active substances is controlled. Redwood Pharma can also improve the dosing of other established drugs with IntelliGel®. Redwood Pharma's strength lies in the formulation and early clinical development. Revenue will be generated through licensing agreements with pharmaceutical companies that have the resources to manufacture and sell products worldwide.

Redwood Pharma AB (publ) is the listing on AktieTorget (symbol: REDW, ISIN: SE008294789). For more information see
www.redwoodpharma.se

About Us

The firm is a pharmaceutical company focused on development of new ophthalmic therapies where there are clear and unmet clinical needs. Redwood Pharma’s lead product in development is a new eye drop designed to treat an underlying cause of chronic Dry Eye Disease in post-menopausal women. Through the IntelliGel® drug delivery platform, a technology developed for controlled release, the company creates exciting opportunities to improve existing therapies and also to develop new ones.